These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 19202127)

  • 1. Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells.
    Lundqvist A; Yokoyama H; Smith A; Berg M; Childs R
    Blood; 2009 Jun; 113(24):6120-7. PubMed ID: 19202127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity.
    Lundqvist A; Abrams SI; Schrump DS; Alvarez G; Suffredini D; Berg M; Childs R
    Cancer Res; 2006 Jul; 66(14):7317-25. PubMed ID: 16849582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition.
    Hallett WH; Ames E; Motarjemi M; Barao I; Shanker A; Tamang DL; Sayers TJ; Hudig D; Murphy WJ
    J Immunol; 2008 Jan; 180(1):163-70. PubMed ID: 18097016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition.
    Ames E; Hallett WH; Murphy WJ
    Clin Exp Immunol; 2009 Mar; 155(3):504-13. PubMed ID: 19220837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses.
    Salagianni M; Lekka E; Moustaki A; Iliopoulou EG; Baxevanis CN; Papamichail M; Perez SA
    J Immunol; 2011 Mar; 186(6):3327-35. PubMed ID: 21317394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid suppressor cell depletion augments antitumor activity in lung cancer.
    Srivastava MK; Zhu L; Harris-White M; Kar UK; Huang M; Johnson MF; Lee JM; Elashoff D; Strieter R; Dubinett S; Sharma S
    PLoS One; 2012; 7(7):e40677. PubMed ID: 22815789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells.
    Sarhan D; Wennerberg E; D'Arcy P; Gurajada D; Linder S; Lundqvist A
    Cancer Immunol Immunother; 2013 Aug; 62(8):1359-68. PubMed ID: 23689729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.
    Shanker A; Brooks AD; Tristan CA; Wine JW; Elliott PJ; Yagita H; Takeda K; Smyth MJ; Murphy WJ; Sayers TJ
    J Natl Cancer Inst; 2008 May; 100(9):649-62. PubMed ID: 18445820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.
    Brooks AD; Jacobsen KM; Li W; Shanker A; Sayers TJ
    Mol Cancer Res; 2010 May; 8(5):729-38. PubMed ID: 20442297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.
    Feng X; Yan J; Wang Y; Zierath JR; Nordenskjöld M; Henter JI; Fadeel B; Zheng C
    Mol Immunol; 2010 Aug; 47(14):2388-96. PubMed ID: 20542572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance.
    Cao X; Cai SF; Fehniger TA; Song J; Collins LI; Piwnica-Worms DR; Ley TJ
    Immunity; 2007 Oct; 27(4):635-46. PubMed ID: 17919943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-κB crosstalk.
    Thounaojam MC; Dudimah DF; Pellom ST; Uzhachenko RV; Carbone DP; Dikov MM; Shanker A
    Oncotarget; 2015 Oct; 6(32):32439-55. PubMed ID: 26431276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutting edge: bortezomib-treated tumors sensitized to NK cell apoptosis paradoxically acquire resistance to antigen-specific T cells.
    Lundqvist A; Su S; Rao S; Childs R
    J Immunol; 2010 Feb; 184(3):1139-42. PubMed ID: 20026740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells.
    Berg M; Lundqvist A; McCoy P; Samsel L; Fan Y; Tawab A; Childs R
    Cytotherapy; 2009; 11(3):341-55. PubMed ID: 19308771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of bortezomib in sensitizing human prostate cancer cell lines to NK-mediated cytotoxicity.
    Hu W; Zheng RR; Cui HX; Yue D; Wang Y; Jiang YH
    Asian J Androl; 2012 Sep; 14(5):695-702. PubMed ID: 22902909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib and IL-12 produce synergetic anti-multiple myeloma effects with reduced toxicity to natural killer cells.
    Wang X; Feng X; Wang J; Shao N; Ji C; Ma D; Henter JI; Fadeel B; Zheng C
    Anticancer Drugs; 2014 Mar; 25(3):282-8. PubMed ID: 24300915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer.
    Smyth MJ; Teng MW; Swann J; Kyparissoudis K; Godfrey DI; Hayakawa Y
    J Immunol; 2006 Feb; 176(3):1582-7. PubMed ID: 16424187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma.
    Armeanu S; Krusch M; Baltz KM; Weiss TS; Smirnow I; Steinle A; Lauer UM; Bitzer M; Salih HR
    Clin Cancer Res; 2008 Jun; 14(11):3520-8. PubMed ID: 18519785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8
    Puca E; Probst P; Stringhini M; Murer P; Pellegrini G; Cazzamalli S; Hutmacher C; Gouyou B; Wulhfard S; Matasci M; Villa A; Neri D
    Int J Cancer; 2020 May; 146(9):2518-2530. PubMed ID: 31374124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling.
    Wennerberg E; Sarhan D; Carlsten M; Kaminskyy VO; D'Arcy P; Zhivotovsky B; Childs R; Lundqvist A
    Int J Cancer; 2013 Oct; 133(7):1643-52. PubMed ID: 23504627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.